FZ 002 - Guangzhou Fermion Technology
Alternative Names: FZ-002 - Guangzhou Fermion Technology; FZ002-037Latest Information Update: 23 Jan 2024
At a glance
- Originator Guangzhou Fermion Technology
- Class Gene therapies; Non-opioid analgesics; Small molecules
- Mechanism of Action Somatostatin receptor subtype 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 10 Jan 2024 Guangzhou Fermion Technology completes a phase I trial in Pain (In volunteers) in China (PO)
- 10 Jan 2024 Guangzhou Fermion Technology plans phase II trial in Pain (PO)
- 22 May 2023 FZ 002 - Guangzhou Fermion Technology is available for licensing as of 22 May 2023. https://www.fulmz.com/pipeline#tit2